Skip to main content

Table 1 Patient characteristics according to extent of disease

From: Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis

Extent of disease Pancolitis Left-sided colitis Proctitis
Patients (total 133) 61 (46%) 48 (36%) 24 (18%)
Age at the endoscopy (year), median (IQR) 37 (27–51) 46 (33–55) 44 (37–57)
Total number of endoscopies (total 162) 79 (49%) 58 (36%) 25 (15%)
Clinical activity (total 125)
 Remission stage (LI < 4) (total 79) 35 (58%) 30 (61%) 14 (88%)
Active stage (LI  4) (total 46) 25 (42%) 19 (39%) 2 (13%)
Colonoscopy findings (maximum index in the colorectum)
 MES 0 (total 61) 33 (41%) 17 (29%) 11 (44%)
 MES 1 (total 43) 18 (23%) 16 (28%) 9 (36%)
 MES 2 (total 45) 20 (26%) 21 (36%) 4 (16%)
 MES 3 (total 13) 8 (10%) 4 (7%) 1 (4%)
Concomitant medications
 Oral 5-ASA 68 (85%) 53 (91%) 10 (40%)
 Topical 5-ASA 5 (6%) 7 (12%) 11 (44%)
 Oral steroids 4 (5%) 1 (2%) 0
 Topical steroids 1 (1%) 6 (10%) 5 (20%)
 Immunomodulators 24 (3%) 14 (24%) 0
 Tacrolimus 0 1 (2%) 0
 Infliximab 16 (2%) 6 (10%) 0
 Adalimumab 7 (9%) 2 (3%) 0
 Golimumab 2 (3%) 1 (2%) 0
 Tofacitinib 1 (1%) 0 0